Oxford Immunotec Global PLC Form 3

February 02, 2016

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

**OMB APPROVAL** 

**OMB** Number:

3235-0104

Expires:

response...

January 31, 2005

0.5

Estimated average burden hours per

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES** 

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting

Person \*

BALTHROP PATRICK J

(Last)

(First)

(Middle)

Statement

(Month/Day/Year)

01/29/2016

2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol Oxford Immunotec Global PLC [OXFD]

> 4. Relationship of Reporting 5. If Amendment, Date Original

Person(s) to Issuer

Filed(Month/Day/Year)

C/O OXFORD IMMUNOTEC GLOBAL PLC, 94C INNOVATION DRIVE

(Street)

10% Owner \_X\_ Director Officer \_ Other

(give title below) (specify below)

(Check all applicable)

6. Individual or Joint/Group Filing(Check Applicable Line) \_X\_ Form filed by One Reporting

Person

Form filed by More than One

Reporting Person

ABINGDON. OXFORDSHIRE, X0Â OX14 4RZ

> (City) (State)

1. Title of Security (Instr. 4)

(Zip)

2. Amount of Securities Beneficially Owned

(Instr. 4)

Ownership

Form:

Table I - Non-Derivative Securities Beneficially Owned

4. Nature of Indirect Beneficial Ownership

(Instr. 5)

Direct (D) or Indirect (I) (Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)

**Expiration Date** (Month/Day/Year)

2. Date Exercisable and 3. Title and Amount of Securities Underlying **Derivative Security** (Instr. 4)

4. 5. Ownership Conversion or Exercise Form of Price of Derivative Derivative Security:

6. Nature of Indirect Beneficial Ownership (Instr. 5)

1

### Edgar Filing: Oxford Immunotec Global PLC - Form 3

Date Expiration Title Amount or Security Direct (D)

Exercisable Date Number of Shares (I)

(Instr. 5)

# **Reporting Owners**

Reporting Owner Name / Address  $\begin{array}{c} \text{Relationships} \\ \\ \text{Director} \end{array} \begin{array}{c} 10\% \\ \text{Owner} \end{array} \begin{array}{c} \text{Officer} \end{array} \begin{array}{c} \text{Other} \end{array}$ 

BALTHROP PATRICK J
C/O OXFORD IMMUNOTEC GLOBAL PLC
94C INNOVATION DRIVE
ABINGDON, OXFORDSHIRE, X0Â OX14 4RZ

# **Signatures**

/s/ Elizabeth M. Keiley, as Attorney-in-Fact for Patrick J.
Balthrop, Sr

\*\*Signature of Reporting Person Date

# **Explanation of Responses:**

No securities are beneficially owned

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2